PainTEQ Appoints MedTech Veteran Robert Kline to Board to Support Strategic Growth
Tampa, FL-based PainTEQ has appointed medical technology executive Robert Kline to its Board of Directors as the company advances the commercial scale-up of its LinQ SI joint stabilization system. The move follows a growth recapitalization and is intended to strengthen the company’s strategic execution in interventional spine care.
Kline brings more than 25 years of experience leading medical device companies from early commercialization through acquisition. He previously founded Medivance, which was acquired by C. R. Bard (now Becton Dickinson), co-founded ViroCyt before its sale to Sartorius, and served as CEO of Bolder Surgical prior to its acquisition by Hologic in 2021.
“PainTEQ has a clear and essential vision for the market,” Kline said. “My decision to join the PainTEQ board was based on a simple fact: the LinQ system works. It provides superior patient outcomes in a highly efficient manner—the gold standard for med-tech innovation.”
PainTEQ Chief Executive Officer Shanth Thiyagalingam said the appointment will support responsible growth and greater adoption of the company’s technology. “Robert Kline’s expertise gives us a powerful strategic advantage, enabling us to expand our mission of clinical excellence built on evidence-backed medicine,” he said.
The LinQ system has been used in more than 14,000 procedures and is designed to provide a minimally invasive alternative to traditional SI joint fusion surgeries. PainTEQ expects Kline’s strategic guidance to further build market momentum as demand grows for interventional approaches to lower back pain.
